Biotech

Alexandria Real Estate Equities (ARE) Stock Plummets to 52-Week Low After Q3 Miss – Can the Biotech REIT Rebound?

Stock Nosedives on Earnings News Pasadena, Calif., Oct. 28, 2025 – Alexandria Real Estate Equities (NYSE: ARE) saw its stock price collapse to a new 52-week low in Tuesday’s trading, as disappointing quarterly

28 October 2025

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Key points: Regeneron (NASDAQ: REGN) shares recently traded around $580–$585 (closing at $585.31 on Oct 27) after a slight pullback earlier in the month investing.com. Over the past week REGN is up

28 October 2025

Earnings Reports · Healthcare Industry · Investment Analysis · NASDAQ:REGN · Pharmaceuticals · Stock Market

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based

28 October 2025

Biotechnology · CRISPR · Investment News · NASDAQ:NTLA · Pharma Industry · Stock Market

Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Stock Skyrockets on Saudi Arabia Deal Announcement Co-Diagnostics’ stock price erupted on Monday after the company unveiled a strategic joint venture in the Middle East. Shares of the small-cap diagnostics firm opened around

27 October 2025

Biotechnology · Company News · Financial Analysis · Investing · NASDAQ:CODX · Stock Market

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago

27 October 2025

Biotechnology · Clinical Trials · Mergers & Acquisitions · NASDAQ:RNA · NYSE:NVS · Pharmaceutical Industry · Stock Market

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the

26 October 2025

Biotech · Mergers & Acquisitions · Pharmaceuticals · Rare Diseases · Stock Market

Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

AI-Driven “TechBio” Strategy Recursion’s narrative centers on its AI-enhanced drug discovery platform. Founded in 2013 in Salt Lake City, Recursion has spent years building RecursionOS, a giant database of cellular images and

26 October 2025

Artificial Intelligence · Biotechnology · Drug Discovery · Investing · NASDAQ:RXRX · Stock Market

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Sources: Official press releases and filings investors.adverum.com investors.adverum.com, Reuters, Investing.com, Fierce Biotech fiercebiotech.com, and analyst reports marketbeat.com marketbeat.com. All data as of market close Oct. 23, 2025 and news through Oct. 24,

24 October 2025

Biotech News · Gene Therapy · Investing · Mergers and Acquisitions · NASDAQ:ADVM · NYSE:LLY · Stock Market

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next?

Scienture’s unprecedented Oct. 23 rally was driven by the commercial rollout of Arbli, its first revenue-generating product. The company’s press release on Oct. 23 confirmed that it began sales and shipped first

24 October 2025

Company Analysis · FDA Approvals · Investment Trends · NASDAQ:SCNX · Pharma News · Stock Market

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

SCNX Stock Soars on Arbli Launch News Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the

23 October 2025

FDA Approvals · Investment News · Market Trends · Pharmaceuticals · Stock Market

Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish

Stock Performance and Recent Rally Ventyx Biosciences has been one of 2025’s biggest small-cap biotech movers. The Nasdaq-listed stock jumped sharply on Oct. 22 after hours, when the company announced the positive

23 October 2025

Biotech News · Financial Trends · Health Innovations · Investment Analysis · NASDAQ:VTYX · Stock Market

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Stock Performance & Analyst Sentiment Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year

22 October 2025

Biotech News · Financial Analysis · Investment Tips · NASDAQ:ARCT · Pharma Industry · Stock Market